medigraphic.com
ISSN 0016-3813 (Print)

2005, Number 6

<< Back Next >>

Gac Med Mex 2005; 141 (6)

Leptine participation in the development of liver steatosis and biliar lithiasis.

Méndez-Sánchez N, Ponciano-Rodríguez G, Chávez-Tapia NC, Uribe M

Language: Spanish
References: 55
Page: 496-500
PDF size: 59.88 Kb.


ABSTRACT

Obesity increases significantly the risk of developing several common gastrointestinal diseases such as gallstone disease (GD) and hepatic steatosis (HS). Elsewhere we have shown a relationship between HDL cholesterol, cholesterol saturation index, and leptin in obese patients loosing weight. Furthermore, leptin plays an important role facilitating HS and possibly in the associated inflammatory process. The aim of this study was to investigate the relationship between GD and HS. The sample was comprised by patients attending the unit for check-up. Subjects with visible stones or HS by ultrasound (cases) were compared with healthy controls. Demographic and body mass index (BMI) were recorded. Plasma leptin, insulin and serum lipids and lipoproteins levels were measured by standard methods. A total of 317 subjects were included in this study. They were divided in four groups as follows: GD (n=100), HS (n=84), GD + HS (n=33) and controls (n=100). The control group was significantly older (GD, 52.6 ± 11.6; HS, 49.8 ± 11.1; GD +HS, 51.6 ± 10.5; 57.1 ± 7.4), p‹ 0.05. BMI was higher in the HS groups (28.7 ± 2.8) and GD +EH (29.0 ± 3.8) than in the GD (27.4 ± 4.3) and control (27.0 ± 3.1) group, p‹ 0.05. The GD group displayed the highest leptin levels (13.7 241 8.1), P ‹ 0.05, whereas insulin levels were similar in all groups. Since GD and HS subjects have high plasma leptin levels compared with controls, our results suggest that leptin plays an important role in the pathophysiology of GD and HS.


REFERENCES

  1. Aguilar-Salinas CA, Vázquez-Chávez C, Gamboa-Marrufo R, García-Soto N, de Jesús Ríos-González J, Holguín R, et al. Obesity, diabetes, hypertension, and tobacco consumption in an urban adult Mexican population. Arch Med Res 2001;32:446-53.

  2. 2. Arroyo P, Loria A, Mendez O. Changes in the household calorie supply during the 1994 economic crisis in Mexico and its implications on the obesity epidemic. Nutr Rev 2004;62:S163-8.

  3. 3. del Río-Navarro BE, Velázquez-Monroy O, Sánchez-Castillo CP, Lara-Esqueda A, Berber A, Fanghanel G, et al. The high prevalence of overweight and obesity in Mexican children. Obes Res 2004;12:215-223.

  4. 4. Villa AR, Escobedo MH, Méndez-Sánchez N. Estimates and trends of obesity prevalence through mortality rates associated of chronic diseases in Mexico. Cac Med Mex 2004;140(Suppl 2):S21-S25.

  5. 5. Sánchez-Castillo CP. Epidemiología de la obesidad, in Obesidad: epidemiología, fisiopatología, y manifestaciones clínicas, Méndez-Sánchez N, Uribe M, Editors, México. Manual Moderno: 2002. p. 5-31.

  6. 6. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 Jama 2003;289:76-79.

  7. 7. Méndez-Sánchez N, Sánchez-Castillo CP, Villar AR, Madrigal H, Merino B, García E, et al. Relación entre sobrepeso y obesidad con mortalidad por cirrosis hepática en México. Rev Gastr Mex 2003;68:176.

  8. 8. Méndez-Sánchez N, Sánchez-Castillo CP, Villa AR, Madrigal H, Merino B, García E, et al. The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico. Ann Hepatol 2004;3:66-71.

  9. 9. Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004;141:946-56.

  10. Bennion LJ, Grundy SM. Effects of obesity and caloric intake on biliary lipid metabolism in mano J Clin Invest 1975; 56: 996-1011.

  11. StahIberg D, Rudling M, Angelin B, Bjorkhem I, Forsell P, Nilsell K, et al. Hepatic cholesterol metabolism in human obesity. Hepatology 1997;25:1447-50.

  12. Lizardi-Cervera J, Motola-Kuba D, Guevara-Gonzalez L. Obesity and its association with cryptogenic cirrhosis and hepatocarcinoma. Gac Med Mex 2004;140(Suppl 2):S77-83.

  13. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.

  14. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79.

  15. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.

  16. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.

  17. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-7.

  18. Nakao K, Nakata K, Ohtsubo N, Maeda M, Moriuchi T, Ichikawa T, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002;97:1796-1801.

  19. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.

  20. Méndez-Sánchez N, Sánchez-Lara K, Villa AR, Bahena-Aponte J, Chávez Tapia NC, Ramos MH, et al. Adiponectin concentration as protective factor in hepatic steatosis. WorldJ Gas troen terol 2005; in press.

  21. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004;50:1511-1525.

  22. Méndez-Sánchez N, González V, King-Martínez AC, Sánchez H, Uribe M. Plasma leptin and the cholesterol saturation of bile are correlated in obese women after weight loss. J Nutr 2002; 132: 2195-8.

  23. Méndez-Sánchez N, Chávez-Tapia N, Uribe M. Effects of leptin on biliary lipids: potential consequences for gallstone formation and therapy in obesity. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:in press.

  24. Méndez-Sánchez N, Chávez- Tapia NC, Uribe M. [Obesity and non-alcoholic steatohepatitis]. Gac Med Mex 2004;140(Supp12):567-72.

  25. Méndez-Sánchez N, Chávez-Tapia NC, Uribe M. An update on non alcoholic fatty liver disease. Rev Invest Clin 2004; 56: 72-82.

  26. Li Z, Un H, Yang S, Diehl AM. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002;123:1304-1310.

  27. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.

  28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

  29. Duggirala R, Mitchell BD, Blangero J, Stern MP. Genetic determinants of variation in gallbladder disease in the Mexican-American population. Genet Epidemiol 1999;16:191-204.

  30. Ruhl CE, Everhart JE. Relationship of serum leptin concentration and other measures of adiposity with gallbladder disease. Hepatology 2001;34:877-83.

  31. Ko CW, Beresford SA, Schulte SJ, Matsumoto AM, Lee SP. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 2005;41:359-365.

  32. Graewin SJ, Lee K, Tran KQ, Goldblatt MI, Svatek CL, Nakeeb A, et al. Leptin-resistant obese mice do not from biliary crystals on a high cholesterol diet. J Surg Res 2003;114:291.

  33. Graewin SJ, Lee KH, Tran KQ Goldblatt MI, Svatek CL, Nakeeb A, et al. Leptin-resistant obese mice do not form biliary crystals on a high cholesterol diet. J Surg Res 2004;122:145-149.

  34. Graewin SJ, Kiely JM, Lee KH, Svatek CL, Nakeeb A, Pitt HA. Nonobese diabetic mice have diminished gallbladder motility and shortened crystal observation time. J Gastrointest Surg 2004; 8: 824-9; discussion 829-30.

  35. Graewin SJ, Lee KH, Kiely JM, Svatek CL, Nakeeb A, Pitt HA. Gallbladder myocytes are short and cholecystokinin-resistant in obese diabetic mice. Surgery 2004;136:431-436.

  36. Tran KQ Goldblatt MI, Swartz-Basile DA, Svatek C, Nakeeb A, Pitt HA. Diabetes and hyperlipidemia correlate with gallbladder contractility in leptin-related murine obesity. J Gastrointest Surg 2003;7:857-62; discussion 863.

  37. Tran KQ, Graewin SJ, Swartz-Basile DA, Nakeeb A, Svatek CL, Pitt HA. Leptin-resistant obese mice have paradoxically low biliary cholesterol saturation. Surgery 2003; 134: 372-7.

  38. Tran KQ, Swartz-Basile DA, Nakeeb A, Pitt HA. Gallbladder motility in agouti-yellow and leptin-resistant obese mice. J Surg Res 2003; 113: 56-61.

  39. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-6.

  40. Un HZ, Yang SQ, Chuekaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.

  41. Tobe K, Ogura T, Tsukamoto C, Imai A, Matsuura K, Iwasaki Y, et al. Relationship between serum leptin and fatty liver in Japanese male adolescent university students. Am J Gastroenterol 1999;94:3328-35.

  42. Giannini E, Botta F, Cataldi A, Teneoni GL, Ceppa P, Barreea T, et al. Leptin levels in nonalcoholic steatohepatitis and chronie hepatitis C. Hepatogastro-enterology 1999;46:2422-2425.

  43. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000;95:3584-3589.

  44. Yang S, Lin H, DiehI AM. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappa B induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 2001;281:G382-92.

  45. Leclercq lA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37:206-13.

  46. Tomita K, Azuma T, Kitamura N, Tamiya G, Ando S, Nagata H, et al. Leptin deficiency enhances sensitivity of rats to alcoholic steatohepatitis through suppression of metallothionein. Am J Physiol Gastrointest Liver Physiol 2004;287:G1078-G1085.

  47. Baffy G, Zhang CY, Glickman JN, Lowell BB. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology 2002;35:753-761.

  48. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;41:943-949.

  49. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.

  50. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003;98:2771-2776.

  51. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-50.

  52. Liangpunsakul S, Chalasani N. Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol 2004;38:891-897.

  53. Gunel N, Coskun U, Toruner FB, Sancak B, Yilmaz E, Cengiz O, et al. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis. Curr Med Res Opin 2003;19:47-50.

  54. Serin E, Ozer B, Gumurdulu Y, Kayaselcuk F, Kul K, Boyacioglu S. Serum leptin level can be a negative marker of hepatocyte damage in nonalcoholic fatty liver. J Gastroenterol 2003;38:471-476.

  55. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002;36:403-409.




2020     |     www.medigraphic.com